1. A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2). (11th May 2022) Authors: Lazarus, Howard M.; Denning, Jill; Wring, Stephen; Palacios, Michelle; Hoffman, Sidra; Crizer, Katelyn; Kamau‐Kelley, Watiri; Symonds, William; Feldman, Jeremy Journal: Pulmonary circulation Issue: Volume 12:Number 2(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension. (22nd August 2022) Authors: Nikkho, Sylvia M.; Richter, Manuel J.; Shen, Eric; Abman, Steven H.; Antoniou, Katerina; Chung, Jonathan; Fernandes, Peter; Hassoun, Paul; Lazarus, Howard M.; Olschewski, Horst; Piccari, Lucilla; Psotka, Mitchell; Saggar, Rajan; Shlobin, Oksana A.; Stockbridge, Norman; Vitulo, Patrizio; Vizza, Ca... Journal: Pulmonary circulation Issue: Volume 12:Number 3(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A retrospective study of in-hospital mortality in patients with idiopathic pulmonary fibrosis between 2015 and 2018. Issue 47 (20th November 2020) Authors: Durheim, Michael T.; Judy, Jennifer; Bender, Shaun; Neely, Megan L.; Baumer, Dorothy; Robinson, Scott B.; Conoscenti, Craig S.; Leonard, Thomas B.; Lazarus, Howard M.; Palmer, Scott M. Other Names: Mubarak. Muhammed section editor. Journal: Medicine Issue: Volume 99:Issue 47(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗